Investigator

Roberto Coppo

Program-Specific Associate Professor · Kyoto University, Dept. of Clinical Bio-Resource Research and Development, Kyoto University, Graduate School of Medicine

Research Interests

RCRoberto Coppo
Papers(1)
Clonal Origin and Lin…
Collaborators(5)
Yoji KukitaAya NakajimaKikuya KatoKunishige OnumaMasahiro Inoue
Institutions(2)
Kyoto UniversityOsaka International C…

Papers

Clonal Origin and Lineage Ambiguity in Mixed Neuroendocrine Carcinoma of the Uterine Cervix

Small-cell neuroendocrine carcinoma (SCNEC) of the cervix is a rare disease characterized by a high incidence of mixed tumors with other types of cancer. The mechanism underlying this mixed phenotype is not well understood. This study established a panel of organoid lines from patients with SCNEC of the cervix and ultimately focused on one line, which retained a mixed tumor phenotype, both in vitro and in vivo. Histologically, both organoids and xenograft tumors showed distinct differentiation into either SCNEC or adenocarcinoma in some regions and ambiguous differentiation in others. Tracking single cells indicated the existence of cells with bipotential differentiation toward SCNEC and adenocarcinomas. Single-cell transcriptional analysis identified three distinct clusters: SCNEC-like, adenocarcinoma-like, and a cluster lacking specific differentiation markers. The expression of neuroendocrine markers was enriched in the SCNEC-like cluster but not exclusively. Human papillomavirus 18 E6 was enriched in the SCNEC-like cluster, which showed higher proliferation and lower levels of the p53 pathway. After treatment with anticancer drugs, the expression of adenocarcinoma markers increased, whereas that of SCNEC decreased. Using a reporter system for keratin 19 expression, changes in the differentiation of each cell were shown to be associated with the shift in differentiation induced by drug treatment. These data suggest that mixed SCNEC/cervical tumors have a clonal origin and are characterized by an ambiguous and flexible differentiation state.

19Works
1Papers
5Collaborators
NeoplasmsDrug Resistance, Neoplasm

Positions

2025–

Program-Specific Associate Professor

Kyoto University · Dept. of Clinical Bio-Resource Research and Development, Kyoto University, Graduate School of Medicine

2024–

Postdoctoral Research Fellow

Kyoto University · Dept. of Clinical Bio-Resource Research and Development, Kyoto University, Graduate School of Medicine

2022–

JSPS Postdoctoral Research Fellow

Kyoto University · Dept. of Clinical Bio-Resource Research and Development, Kyoto University, Graduate School of Medicine

2018–

Postdoctoral Research Fellow

Kyoto University · Dept. of Clinical Bio-Resource Research and Development, Kyoto University, Graduate School of Medicine

2017–

Postdoctoral Research Fellow

Osaka International Cancer Institute · Dept. of Biochemistry

2013–

Ph.D. Fellow

University of Turin · Molecular Biotechnology Center, School of Medicine, Dept. Molecular Biotechnology and Health Sciences

Education

2017

PhD in Biomedical Sciences and Oncology

University of Turin · Molecular Biotechnology Center, School of Medicine, Dept. Molecular Biotechnology and Health Sciences

2012

Master’s Degree in Molecular Biotechnology

University of Turin · Molecular Biotechnology Center, School of Medicine, Dept. Molecular Biotechnology and Health Sciences

2010

Bachelor's Degree in Biotechnology

University of Eastern Piedmont Amadeo Avogadro · Dept. of Health Sciences

Country

JP

Keywords
Tumor organoidsCancer cell plasticityDrug resistance